Answers are grounded in this paper and cite their sources.
Aberrantly glycosylated membrane proteins represent promising targets for cancer immunotherapy. However, glycan diversity and heterogeneity pose a challenge to developing effective vaccines against tumors expressing different glycoantigens. To broaden the immune response and enhance the vaccine's efficacy by targeting a wide variety of glycosylation patterns on tumor cells, herein we developed a Mosaic glycopeptide vaccine by simultaneously presenting three different glycopeptides on the carrier protein tetanus toxoid (TT). Immunological evaluation revealed that the Mosaic vaccine elicited higher antibody titers than single-glycopeptide formulations, primarily mediating tumor cell lysis via antibody-dependent cellular cytotoxicity (ADCC) and significantly suppressing tumor growth in both wild-type and transgenic murine models. Notably, the Mosaic vaccine exhibited not only preventive but also therapeutic effects, demonstrating clear antitumor activity in transgenic mice. Combination therapy with PD-1 blockade further enhanced antitumor efficacy. In-depth mechanistic studies demonstrated that the Mosaic vaccine effectively activated antigen-presenting cells and T cells. Furthermore, serum antibodies from Mosaic vaccine-immunized mice exhibited selective binding to patient-derived pancreatic tumor tissues, suggesting their clinical translational potential.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: